ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1)
(2021) SBN — Location: Virtuel (27.May.2021)
Files
No attached file found for this publication.
Details
- Authors
- Affiliations
Citations
Devresse, A., Deschenes, G., Cochat, P., Magen, D., van’t Hoff, W., Michael, M., Sas, D., Schalk, G., Shasha-Lavsky, H., Hayes, W., Bae, K., Seddighzadeh, A., Garg, P., Vaishnaw, A., McGregor, T., Fujita, K., & Frishberg, Y. (2021). ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1). SBN, Virtuel. https://hdl.handle.net/2078.5/243863